Retinal pigment epithelial cells as a therapeutic tool and target against retinopathies

Drug Discov Today. 2018 Sep;23(9):1672-1679. doi: 10.1016/j.drudis.2018.06.009. Epub 2018 Jun 13.

Abstract

Retinal pigment epithelium (RPE) is a cell monolayer essential for photoreceptor function and forming the blood-retinal barrier. RPE and retinal neurons share the same origin and a polarized cytoarchitecture. Several factors determine the phagocytosis and permeability of RPE, influencing photoreceptor renewal and drug delivery, efficacy and toxicity. Adult human RPE expresses neuronal markers in vitro, indicating a potential transdifferentiation. Degeneration of the RPE leads to death of photoreceptors and retinal neurons, resulting in the vision loss of retinopathy. Here, we suggest tools for cell engineering to discover new ways for activating the endogenous regeneration of barrier functions and/or of the retinal precursors in RPE cells.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Administration, Ophthalmic
  • Animals
  • Cell Line
  • Drug Delivery Systems
  • Drug Discovery / methods*
  • Gene Expression Regulation
  • Gene Transfer Techniques*
  • Genotype
  • Humans
  • Molecular Targeted Therapy
  • Phenotype
  • Retinal Diseases / genetics
  • Retinal Diseases / metabolism
  • Retinal Diseases / pathology
  • Retinal Diseases / therapy*
  • Retinal Pigment Epithelium / drug effects*
  • Retinal Pigment Epithelium / metabolism
  • Retinal Pigment Epithelium / pathology
  • Signal Transduction / drug effects